TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06278922

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Seeking Safety + Signs of Safety toolkit
Description: Signs of Safety is a Deaf-accessible toolkit to be used with the Seeking Safety treatment protocol. Seeking Safety is a manualized, non-exposure-based, cognitive behavioral therapy for trauma and addiction.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: NDT therapists come from a wide variety of training backgrounds, but each works with their clients to build on their existing strengths and provide support as clients develop new strategies and behaviors for overcoming adversity.
Study: NCT06473532

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TEXT4HF
Description: In addition to usual care, participants in the intervention group will receive 5 TMs/week for 12 weeks at a time of their preference. Tailoring of the TMs is performed based on participants' responses to validated questionnaires (health beliefs scales, HF-knowledge scale, and self-efficacy about HF self-care scale), administered at baseline and 4 weeks. They will also receive an AHA HF discharge informational packet.
Study: NCT06176248

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide
Description: 1 injection of local anaesthetic (5 ml levobupivacaine 2.5 mg/mL) opposite the subscapular nerve, under ultrasound control, in a lateral decubitus or sitting position. Subsequently, they underwent Xray-controlled arthrodistension by injection of 1 ml of Triamcinolone Acetonide, combined with 10 ml of visipaque 270 contrast medium and 5 ml of Xylocaine.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline solution
Description: intramuscular injection of 1 ml saline under ultrasound control under the same conditions as the experimental group. Subsequently, they will undergo Xray-controlled arthrodistension under the same conditions as the experimental group
Study: NCT04933500

Intervention type: DEVICE
Intervention: Whitacre spinal needle
Description: 25G Whitacre spinal needle
Study: NCT05588440

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ONCT-808
Description: A single infusion of ONCT-808 autologous CAR-T cell infusion will be administered intravenously~Phase 1: Dose Escalation with bridging therapy as needed~Phase 2: Patients with LBCL or MCL will be enrolled into two separate dose expansion cohorts.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ONCT-808
Description: A single infusion of ONCT-808 autologous CAR-T cell infusion will be administered intravenously~Phase 1: Dose Escalation with bridging therapy as needed~Phase 2: Patients with LBCL or MCL will be enrolled into two separate dose expansion cohorts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bridging Therapy
Description: Bridging therapy can be oral chemotherapy or IV radiotherapy/chemotherapy per institution's guidelines

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bridging Therapy
Description: Bridging therapy can be oral chemotherapy or IV radiotherapy/chemotherapy per institution's guidelines
Study: NCT05362292

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tolterodine Tartrate ER
Description: Anticholinergic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirabegron
Description: Beta-3-adrenergic agonist

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo pill
Study: NCT06390956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirtobrutinib
Description: Administered once daily as an oral medication.
Study: NCT04900636

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telemedicine Arm
Description: Patients with DM1 ≥ 18 years of age, users of closed loop hybrid systems, assigned to a follow-up program using a telemedicine platform combined with face-to-face visits according to protocol.
Study: NCT05171166

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HAIC
Description: Hepatic arterial infusion chemotherapy is consist of oxaliplatin (35 mg/m2 for 2 hours), followed by 5-fluorouracil (600 mg/m2 for 22 hours) on day1-3 every 4 weeks. For each cycle, leucovorin calcium 200 mg/m2 would be intravenously administered for 2 hours from beginning of 5-fluorouracil infusion.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: A standard hepatic artery catheter would be introduced via the femoral artery percutaneously. Selective catheterization of the proper hepatic artery would be performed using standard diagnostic catheters and fluoroscopic guidance. In the event of multiple arterial supply, the proportion of the liver supplied by each artery would be estimated by the arteriography. After optimal positioning of the catheter, cTACE or DEB-TACE protocol would be performed to embolize the tumor supplying artery blood flow until the stasis of the supplying artery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TACE
Description: A standard hepatic artery catheter would be introduced via the femoral artery percutaneously. Selective catheterization of the proper hepatic artery would be performed using standard diagnostic catheters and fluoroscopic guidance. In the event of multiple arterial supply, the proportion of the liver supplied by each artery would be estimated by the arteriography. After optimal positioning of the catheter, cTACE or DEB-TACE protocol would be performed to embolize the tumor supplying artery blood flow until the stasis of the supplying artery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX
Description: oxaliplatin,leucovorin, and 5-FU

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cTACE or DEB-TACE
Description: lipiodol or microspheres that mixed with EPI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cTACE or DEB-TACE
Description: lipiodol or microspheres that mixed with EPI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donafenib
Description: 200 mg of donafenib (consisting of two 100-mg tablets) twice daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donafenib
Description: 200 mg of donafenib (consisting of two 100-mg tablets) twice daily.
Study: NCT06324474

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid
Description: Gengigel syringe containing 1ml of 0.8% HA

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: scaling and root planning
Description: scaling and root planning using ultrasonic scaler
Study: NCT04591496

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral change intervention;
Description: Behavioral change intervention: goal setting, regarding child's diet and parental feeding practices; self-monitoring, with observation and recording of the child's food intake and parental feeding practices; individualized feedback, based on preceding week monitoring and according to the defined objectives, regarding child's and parent's behaviors; modeling and direct suggestions by tailored parent figures; positive reinforcement associated to parents' accomplishment of the objectives; prompts, to remember the defined objectives and the main messages of the intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Education
Description: Health education: provision of information about preschool children's nutrition guidelines, effective parental feeding practices, strategies to overcome food and feeding-related barriers, and steps to form healthy habits.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Description: Health education: provision of information about preschool children's nutrition guidelines, effective parental feeding practices, strategies to overcome food and feeding-related barriers, and steps to form healthy habits.
Study: NCT05507762

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UC-MSCs
Description: Usage: The stem cell preparation in this study is used intravenously in the elbow.~Dose: The dose of stem cell injection in this clinical study is set at 1×10\^6/Kg/time per injection Duration: 5 injections per trial group for the entire duration of the course, at 1st treatment, 2-week, 4-week, 16-week, and 24-week respectively

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution
Description: Usage: The saline solution in this study is used intravenously in the elbow. Dose: The dose of saline solution in this clinical study is set at 250ml/time per injection Duration: 5 injections per person for the entire duration of the course, at 1st treatment, 2-week, 4-week, 16-week, and 24-week respectively
Study: NCT06360068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfasalazine Tablets
Description: All subjects who meet the inclusion/exclusion criteria will be given sulfasalazine 750mg/dose, twice a day. The dosage will be increased to 1000mg/dose within one month, twice a day if the patient tolerates well.
Study: NCT04073628

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lighting Intervention
Description: Lighting Intervention consisting of a cool or warm light source.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Lighting Intervention
Description: Lighting Intervention consisting of a cool or warm light source.
Study: NCT06324474

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: scaling and root planning
Description: scaling and root planning using ultrasonic scaler
Study: NCT05311033

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exacyl
Description: Healthy males with at risk of post-inflammatory hyperpigmentation have a skin samples for evaluate the activity of tranexamic acid.
Study: NCT05930561

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4D-150 IVT
Description: 4D-150: AAV-based gene therapy comprised of miRNA targeting VEGF-C and codon-optimized sequence encoding aflibercept.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4D-150 IVT
Description: 4D-150: AAV-based gene therapy comprised of miRNA targeting VEGF-C and codon-optimized sequence encoding aflibercept.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4D-150 IVT
Description: 4D-150: AAV-based gene therapy comprised of miRNA targeting VEGF-C and codon-optimized sequence encoding aflibercept.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4D-150 IVT
Description: 4D-150: AAV-based gene therapy comprised of miRNA targeting VEGF-C and codon-optimized sequence encoding aflibercept.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept IVT
Description: Commercially available Active Comparator
Study: NCT05195203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10353
Description: Single or multiple dose(s) of HS-10353

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single or multiple dose(s) of placebo
Study: NCT06305221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opioid-free Analgesics (esketamine, dexmedetomidine)
Description: opioid free group: After infusion of a loading dose of dexmedetomidine, intravenous midazolam 2mg, propofol 2mg kg-1, esketamine 0.5 mg kg-1, rocuronium 0.6-1mg kg-1, and 3min after endotracheal intubation. Intravenous continuous infusion of propofol, esketamine and dexmedetomidine hydrochloride mixture (esketamine 50mg + dexmedetomidine hydrochloride 150 ug + 0.9% saline 50ml in the same 50ml syringe) 0.1ml kg-1 h-1-0.2 ml kg-1 h-1 (equivalent to esketamine 0.1-0.2mg kg-1 h-1; Dexmedetomidine hydrochloride 0.3-0.6 μ g kg-1 h-1) maintains a BIS value between 40-60, 10-20mg / time was added as appropriate.
Study: NCT05900076

Intervention type: DIAGNOSTIC_TEST
Intervention: Curettage for the evacuation of the product of conception
Description: The product of conception taken during the intervention will be recovered at Day 1
Study: NCT06305221

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opioid Anesthetics (sufentanil and remifentanil)
Description: Intravenous midazolam 2mg, propofol 2mg kg-1, sufentanyl 0.3-0.5 μ g kg-1, rocuronium 0.6-1mg kg-1,3min before endotracheal intubation. After successful endotracheal intubation, continuous intravenous infusion of propofol and remifentanil was started to maintain BIS values between 40-60, and rocuronium 10-20mg / time as appropriate. After the start of surgery, 10-20 μ g of sufentanil was added according to blood pressure and heart rate. At the end of the operation, 5mg and 50mg were injected before the end of the operation, and propofol and remifentanil were stopped at the end of the operation
Study: NCT05007548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ga68-Dolacga Injection
Description: Ga68-Dolacga Injection, 2.0±1.0 mCi, single dose, iv bolus
Study: NCT05218057

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ureteroscopic lithotripsy
Description: Ureteroscopic lithotripsy is one of the surgical procedure options for ureteric stone less than 1.5 cm. While many energy systems has been used for stone fragmentation during ureteroscopy, laser energy is the most commonly used approach for stone fragmentation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ureteroscopic lithotripsy
Description: Ureteroscopic lithotripsy is one of the surgical procedure options for ureteric stone less than 1.5 cm. While many energy systems has been used for stone fragmentation during ureteroscopy, laser energy is the most commonly used approach for stone fragmentation.
Study: NCT06194981

Intervention type: DRUG
Intervention: Oxaliplatin and capecitabine/ S-1 and capecitabine
Description: Drug: capecitabine: 1000 mg/m² bid, po, d1-14, oxaliplatin: 130mg/m², iv drip for 2h, d1; S-1: BSA\<1.25m², 40mg bid, 1.25m²≤BSA≤1.5m², 50mg bid, BSA\>1.5m², 60mg bid, po, d1-14, oxaliplatin: 130mg/m², iv drip for 2h, d1

Intervention type: DRUG
Intervention: Oxaliplatin and capecitabine/ S-1 and capecitabine
Description: Drug: capecitabine: 1000 mg/m² bid, po, d1-14, oxaliplatin: 130mg/m², iv drip for 2h, d1; S-1: BSA\<1.25m², 40mg bid, 1.25m²≤BSA≤1.5m², 50mg bid, BSA\>1.5m², 60mg bid, po, d1-14, oxaliplatin: 130mg/m², iv drip for 2h, d1
Study: NCT06098196

Intervention type: DRUG
Intervention: Aminophyllin
Description: Patients will be observationally included in the Elveld TCI or Schnider TCI group and recevied or not Aminiophylline bolus. The TCI model, such as the aminophylline delivery or not, is chosen at anesthesiologist's discretion, as suggested in literature

Intervention type: DRUG
Intervention: Aminophyllin
Description: Patients will be observationally included in the Elveld TCI or Schnider TCI group and recevied or not Aminiophylline bolus. The TCI model, such as the aminophylline delivery or not, is chosen at anesthesiologist's discretion, as suggested in literature
Study: NCT05467930

Intervention type: OTHER
Intervention: Survey
Description: Survey completion by the participant to collect information about health and social experience

Intervention type: OTHER
Intervention: Medical History Review
Description: Review of the participant's medical history at New York Presbyterian/Columbia University Irving Medical Center

Intervention type: OTHER
Intervention: Sample Collection
Description: Collection of nasal and blood samples
Study: NCT06329999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMGV
Description: Initial treatment induction therapy: CMG+Vineclavone regimen Mitoxantrone liposomes 15mg/m2, iv, d1; Cytarabine 10mg/m2, H, q12h, d1-7; G-CSF starts at 5ug/kg, H, d0, WBC ≥ 30 × 109/L, stop G-CSF; Vinecla 100mg, 2200mg, 3400mg, d4-10. Every 4 weeks is a cycle, for a total of 2 cycles. For patients with CR/CRI/MLFS/PR in the first cycle, repeat this regimen for consolidation treatment once (the second course of treatment is Vineclavone 400mg d1-7).~Follow up treatment: Patients who meet the transplantation criteria will undergo hematopoietic stem cell transplantation, while those who do not undergo transplantation will continue to receive CMG+Vineclavone consolidation for 4-6 courses.
Study: NCT06161155

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Protein digestibility
Description: Two protein sources differing in digestiblity will be used in the dietary intervention to create a difference in protein flow into the large intestine, resulting in different levels of protein fermentation.~Participants will swallow an ingestible that senses biomarkers related to protein fermentation.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Protein digestibility
Description: Two protein sources differing in digestiblity will be used in the dietary intervention to create a difference in protein flow into the large intestine, resulting in different levels of protein fermentation.~Participants will swallow an ingestible that senses biomarkers related to protein fermentation.
Study: NCT05297656

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instrument Assisted Soft Tissue Mobilization
Description: Instrument Assisted Soft Tissue Mobilization with graston tecnique and Home exercises programe

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Instrument Assisted Soft Tissue Mobilization
Description: Instrument Assisted Soft Tissue Mobilization to be applied superficially so it is not like a real graston tecnique and Home exercises programe

Intervention type: OTHER
Group type: OTHER
Intervention: Home exercises programe
Description: Only Home exercises programe

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home exercises programe
Description: Only Home exercises programe

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Home exercises programe
Description: Only Home exercises programe
Study: NCT05708768

Intervention type: OTHER
Intervention: Receiving physician manned rapid response car services
Description: All patients receiving services from the physician manned rapid response car will be included
Study: NCT04968366

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous dendritic cells pulsed with multiple neoantigen peptides.
Description: Each dosage of Dendritic Cells (DC) vaccine contains 2-10 million DC cells, loaded with 5-20 tumor neoantigen peptides. DC vaccine will be administered (i.d) around lymph nodes of the groin and Axillary at 2nd, 3rd, 4th, 7th and 11th week after the completion of concurrent Temozolomide chemoradiation. After 5 injections, the investigator will review subject's tolerance and compliance; and, decide whether to administer more DC vaccines up to 8 injections. For certain patients with good tolerance and clinical response of the DC vaccine, peripheral blood is extracted after completion of Temozolomide adjuvant chemotherapy to assess the patient's immune response. According to the result, investigators will decide whether to perform 1-2 more treatment cycles (5-8 injections/cycle) to strengthen the effectiveness

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide adjuvant chemotherapy
Description: Temozolomide is administered as the standard-of-care adjuvant chemotherapy, in combination with the DC vaccines to treat the enrolled patients.
Study: NCT04804930

Intervention type: PROCEDURE
Intervention: picture
Description: We will perform a non-invasive assessment of the scalp with a dermoscope by taking two standardized pictures on the frontal area and the occipital area in order to a blinded analysis of trichoscopic patterns

Intervention type: PROCEDURE
Intervention: picture
Description: We will perform a non-invasive assessment of the scalp with a dermoscope by taking two standardized pictures on the frontal area and the occipital area in order to a blinded analysis of trichoscopic patterns
Study: NCT05136157

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rapid-Acting Insulin
Description: 50 IU of rapid acting insulin taken by a 100 units (1ml) insulin syringe will be added to a 50 ml syringe containing normal saline (NS) to have a total volume of 50 ml with a concentration of 1 IU of insulin per 1 ml of NS

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rapid-Acting Insulin
Description: 50 IU of rapid acting insulin taken by a 100 units (1ml) insulin syringe will be added to a 50 ml syringe containing normal saline (NS) to have a total volume of 50 ml with a concentration of 1 IU of insulin per 1 ml of NS
Study: NCT05957653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine and sufentanil
Description: A total of 20ml of 2% lidocaine and 1μg/ml sufentanil was injected into the bladder through the catheter.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: A total of 20ml normal saline was injected into the bladder through the catheter.
Study: NCT04900766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone Hydrochloride Liposome Injection
Description: 20 mg/m2, IV, on day 1 of each 21-day cycle (q3w).
Study: NCT05884879

Intervention type: BEHAVIORAL
Intervention: Tinnitus simulation
Description: The control group will perform speech perception tests and listening effort tests in the absence and presence of a simulated tinnitus percept using a bone vibrator.
Study: NCT05441995

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Description: Ice packs were applied in the buccal mucosa related to the tooth for 5 minutes after IANB administration

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cryotherapy
Description: Ice packs were applied in the buccal mucosa related to the tooth for 5 minutes after IANB administration
Study: NCT05974917

Intervention type: DEVICE
Intervention: Serious Game (SG)
Description: SG which was conceived as a running game, in which an Avatar runs through the forest and overcomes obstacles through the player's performance of physical exercises.~Children will play while watching an imaginary Avatar, who shows the right movements to perform in order to collect rewards. SG will be projected with a 4K projector and controlled by the child's movements, which will be tracked in markerless mode using Azure's Kinect sensor. SG will include an adaptive tool to enable the experience based on the child's specific motor skills.~The dynamics of SG will be adapted by considering real motor and physiological data acquired during each SG session via a wristband. These data are necessary to keep the child in the aerobic zone (60-80% of maximum heart rate). The movements are:~1. Side bending: Moving an obstacle to open a passage.~2. High jump: Overcoming a low, frontal obstacle.~3. Side lunge: Avoiding a side obstacle.~4. Squat: Passing under a low, frontal obstacle.
Study: NCT05301543

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Behavioral approach 1
Description: Includes changing sleep habits and cognitions around sleep from a mental level

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Behavioral approach 2
Description: Includes changing sleep habits and awarenes of sleep from a perception level
Study: NCT04294355

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artificial intelligence-Assisted colonoscopy
Description: Artificial intelligence-Assisted colonoscopy for detection of colonic polyp

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional colonoscopy
Description: Conventional colonoscopy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional colonoscopy
Description: Conventional colonoscopy